Medical Records: MMRGlobal Goes Into 2012 Highlighting $43 Million in Projected Revenues From Existing Signed Agreements

From MarketWatch:

MMRGlobal, Inc. MMRF -9.77% ("MMR"), a leading provider of Personal Health Records ("PHR"), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals, today announced that going into the upcoming HIMSS Conference and Exhibition, February 20-24, in Las Vegas ( www.himssconference.org ), it has entered into agreements for more than $43 million based on licensing and strategic partnerships pertaining to the Company's biotech and health information technology intellectual property, all of which are specifically described in, and or attached to, MMRGlobal's filings with the Securities and Exchange Commission.

Since the Company's inception, it has invested more than $152 million on biotech and health IT-related Research and Development projects and currently has more than 40 patents issued, pending and or applied for worldwide, including patents pertaining to the Company's FavId(R)/Specifid(TM) vaccine trials and anti-CD20 antibody assets, the second widely believed to be a first cousin to Rituximab. Additionally, MMR's Method and System for Providing Online Medical Records patents were recently valued in a range from $300 million to as much as $800 million ( http://michaelbass.com/PDF/JAN20MMRF.pdf ). The Company also owns other biotech assets including thousands of patient tumor samples believed to be worth additional millions.

"Although the Company's primary business remains the offering of its MyMedicalRecords.com Personal Health Record and MMRPro professional document imaging and scanning solutions, the value of our intellectual property is growing," said Robert H. Lorsch, MMRGlobal Chairman and CEO. "Clearly, as we move into the future, we will seek opportunities to leverage our intellectual property and enter into agreements with strategic partners in patient care and other similar lines of business as well as with companies that specialize in maximizing the value of IP, such as Acacia Research or RPX Corporation and others who have successfully leveraged the values of intellectual property into billions of dollars of valuation for shareholders.